Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Gen KPC"'
Publikováno v:
Bush K. Past and present perspectives on β-lactamases. Vol. 62, Antimicrobial Agents and Chemotherapy. 2018. p. 1–20.
Queenan AM, Bush K. Carbapenemases: The versatile β-lactamases. Clin Microbiol Rev. 2007;20(3):440–58
Ovalle MV, Saavedra SY, González MN, Hidalgo AM, Duarte C, Beltrán M. Resultados de vigilancia nacional de la resistencia antimicrobiana. Biomedica. 2017;37:473–85.
Teo J, Cai Y, Lim T-P, Tan T, Kwa A. Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. Microorganisms. 2016;4(1):13
salme, Timmusk. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales. Front Plant Sci. 2012;0954162(478):1–4.
Vasoo S, Barreto JN, Tosh PK. Emerging Issues in Gram-Negative Bacterial Resistance: An Update for the Practicing Clinician. Mayo Clin Proc [Internet]. 2015;90(3):395–403. Available from: http://dx.doi.org/10.1016/j.mayocp.2014.12.002
Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24(1):1–12.
Villegas MV, Jiménez A, Esparza G, Appel TM. Carbapenemase-producing Enterobacteriaceae: A diagnostic, epidemiological and therapeutic challenge. Infectio. 2019;23(4):388–98.
Vasiliki Tsolaki, a Konstantinos Mantzarlis, a Athanasios Mpakalis, a Ergina Malli, b Fotios Tsimpoukas, c Athanasia Tsirogianni, c Constantinos Papagiannitsis, b Paris 36 Zygoulis, a Maria-Eirini Papadonta, a Efthimia Petinaki, b Demosthenes Makris a EZ. crossm Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically. 2020;64(3):1–11.
Yee R, Dien Bard J, Simner PJ. The Genotype to Phenotype Dilemma: How Should Laboratories Approach Discordant Susceptibility Results? J Clin Microbiol. 2021;(January)
Logan LK, Weinstein RA. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis. 2017;215(Suppl 1):S28–36.
Zhu Y, Huang WE, Yang Q. Clinical Perspective of Antimicrobial Resistance in Bacteria. Infect Drug Resist. 2022;15(March):735–46.
Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents [Internet]. 2017;50(2):127– 34. Available from: http://dx.doi.org/10.1016/j.ijantimicag.2017.03.012
Brink AJ. Epidemiology of carbapenem-resistant Gram-negative infections globally. Curr Opin Infect Dis. 2019;609–16
Lynch JP, Zhanel GG, Clark NM. Infections Due to Acinetobacter baumannii in the ICU: Treatment Options. Semin Respir Crit Care Med. 2017;38(3):311–25
Eichenberger EM, Thaden JT. Epidemiology and mechanisms of resistance of extensively drug resistant gram-negative bacteria. Antibiotics. 2019;8(2)
INS. Informe De Resultados De La Vigilancia Por Laboratorio De Resistencia Antimicrobiana En Infecciones Asociadas a La Atención En Salud (Iaas) 2018 Dirección. Epidemiol las Infecc Asoc a la atención en salud. 2019;29–44.
Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, et al. First detection of the plasmid-mediated class a carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50(8):2880–2.
Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother. 2007;51(4):1553–5.
Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-β-lactamases: Structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64(10):1–20.
Rojo V, Vázquez P, Reyes S, Fuertes LP, Cervero M. Risk factors and clinical evolution of carbapenemase-producing klebsiella pneumoniae infections in a university hospital in Spain. Case-control study. Rev Esp Quimioter. 2018;31(5):427–34.
Friedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-resistant enterobacteriaceae: A strategic roadmap for infection control. Infect Control Hosp Epidemiol. 2017;38(5):580–94.
Ruppé É, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care. 2015;5(1).
Sze DTT, Lau CCY, Chan TM, Ma ESK, Tang BSF. Comparison of novel rapid diagnostic of blood culture identification and antimicrobial susceptibility testing by Accelerate Pheno system and BioFire FilmArray Blood Culture Identification and BioFire FilmArray Blood Culture Identification 2 panels. BMC Microbiol [Internet]. 2021;21(1):1–15. Available from: https://doi.org/10.1186/s12866-021-02403-y
Salimnia H, Fairfax MR, Lephart PR, Schreckenberger P, DesJarlais SM, Johnson JK, et al. Evaluation of the FilmArray Blood Culture Identification Panel: Results of a Multicenter Controlled Trial. J Clin Microbiol. 2016;54(3):687–98.
Schneider JG, Wood JB, Schmitt BH, Emery CL, Davis TE, Smith NW, et al. Susceptibility Provision Enhances Effective De-escalation (SPEED): Utilizing rapid phenotypic susceptibility testing in Gram-negative bloodstream infections and its potential clinical impact. J Antimicrob Chemother. 2019;74:I16–23.
Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis. 2020;7:1–12.
Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(SUPPL. 2):82–9.
Association WM. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013 Sep 22;310(20):2191–4.
Ministerio de salud. RESOLUCION NUMERO 8430 DE 1993. Minsterio de salud. 1993;1–19.
Sotgiu G, Are BM, Pesapane L, Palmieri A, Muresu N, Cossu A, et al. Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study. J Hosp Infect [Internet]. 2018;99(4):413–8. Available from: https://doi.org/10.1016/j.jhin.2018.03.033
Gupta N, Limbago BM, Patel JB, Kallen AJ, Sotgiu G, Are BM, et al. Carbapenem-resistant enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis [Internet]. 2018;53(4):413–8. Available from: https://doi.org/10.1016/j.jhin.2018.03.033
Kunz Coyne AJ, El Ghali A, Holger D, Rebold N, Rybak MJ. Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther [Internet]. 2022;11(2):661–82. Available from: https://doi.org/10.1007/s40121-022-00591-2
Esparza G. Bacterias Gram negativas resistentes a carbapenemicos en Colombia: un desafío continuo al sistema de salud. Infectio. 2020;24(2):55–6.
Marco F. Métodos moleculares para el diagnóstico de septicemia. Enferm Infecc Microbiol Clin. 2017;35(9):586–92.
Salomão MC, Guimarães T, Duailibi DF, Perondi MBM, Letaif LSH, Montal AC, et al. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate. J Hosp Infect.
Remolina S, Escobar C. DESCRIPCIÓN DE TIPOS DE CARBAPENEMASAS EXPRESADAS EN Klebsiella sp. y Pseudomonas aeruginosa EN HOSPITALES DE TERCER NIVEL DE LA CIUDAD DE BOGOTÁ, ESTUDIO DESCRIPTIVO. Univ Nac Colomb. 2018
Tamma PD, Simner PJ. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J Clin Microbiol. 2018;56(11):1–13.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Queenan AM, Bush K. Carbapenemases: The versatile β-lactamases. Clin Microbiol Rev. 2007;20(3):440–58
Ovalle MV, Saavedra SY, González MN, Hidalgo AM, Duarte C, Beltrán M. Resultados de vigilancia nacional de la resistencia antimicrobiana. Biomedica. 2017;37:473–85.
Teo J, Cai Y, Lim T-P, Tan T, Kwa A. Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot. Microorganisms. 2016;4(1):13
salme, Timmusk. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales. Front Plant Sci. 2012;0954162(478):1–4.
Vasoo S, Barreto JN, Tosh PK. Emerging Issues in Gram-Negative Bacterial Resistance: An Update for the Practicing Clinician. Mayo Clin Proc [Internet]. 2015;90(3):395–403. Available from: http://dx.doi.org/10.1016/j.mayocp.2014.12.002
Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24(1):1–12.
Villegas MV, Jiménez A, Esparza G, Appel TM. Carbapenemase-producing Enterobacteriaceae: A diagnostic, epidemiological and therapeutic challenge. Infectio. 2019;23(4):388–98.
Vasiliki Tsolaki, a Konstantinos Mantzarlis, a Athanasios Mpakalis, a Ergina Malli, b Fotios Tsimpoukas, c Athanasia Tsirogianni, c Constantinos Papagiannitsis, b Paris 36 Zygoulis, a Maria-Eirini Papadonta, a Efthimia Petinaki, b Demosthenes Makris a EZ. crossm Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically. 2020;64(3):1–11.
Yee R, Dien Bard J, Simner PJ. The Genotype to Phenotype Dilemma: How Should Laboratories Approach Discordant Susceptibility Results? J Clin Microbiol. 2021;(January)
Logan LK, Weinstein RA. The epidemiology of Carbapenem-resistant enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis. 2017;215(Suppl 1):S28–36.
Zhu Y, Huang WE, Yang Q. Clinical Perspective of Antimicrobial Resistance in Bacteria. Infect Drug Resist. 2022;15(March):735–46.
Kelly AM, Mathema B, Larson EL. Carbapenem-resistant Enterobacteriaceae in the community: a scoping review. Int J Antimicrob Agents [Internet]. 2017;50(2):127– 34. Available from: http://dx.doi.org/10.1016/j.ijantimicag.2017.03.012
Brink AJ. Epidemiology of carbapenem-resistant Gram-negative infections globally. Curr Opin Infect Dis. 2019;609–16
Lynch JP, Zhanel GG, Clark NM. Infections Due to Acinetobacter baumannii in the ICU: Treatment Options. Semin Respir Crit Care Med. 2017;38(3):311–25
Eichenberger EM, Thaden JT. Epidemiology and mechanisms of resistance of extensively drug resistant gram-negative bacteria. Antibiotics. 2019;8(2)
INS. Informe De Resultados De La Vigilancia Por Laboratorio De Resistencia Antimicrobiana En Infecciones Asociadas a La Atención En Salud (Iaas) 2018 Dirección. Epidemiol las Infecc Asoc a la atención en salud. 2019;29–44.
Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, et al. First detection of the plasmid-mediated class a carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother. 2006;50(8):2880–2.
Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob Agents Chemother. 2007;51(4):1553–5.
Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo-β-lactamases: Structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother. 2020;64(10):1–20.
Rojo V, Vázquez P, Reyes S, Fuertes LP, Cervero M. Risk factors and clinical evolution of carbapenemase-producing klebsiella pneumoniae infections in a university hospital in Spain. Case-control study. Rev Esp Quimioter. 2018;31(5):427–34.
Friedman ND, Carmeli Y, Walton AL, Schwaber MJ. Carbapenem-resistant enterobacteriaceae: A strategic roadmap for infection control. Infect Control Hosp Epidemiol. 2017;38(5):580–94.
Ruppé É, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care. 2015;5(1).
Sze DTT, Lau CCY, Chan TM, Ma ESK, Tang BSF. Comparison of novel rapid diagnostic of blood culture identification and antimicrobial susceptibility testing by Accelerate Pheno system and BioFire FilmArray Blood Culture Identification and BioFire FilmArray Blood Culture Identification 2 panels. BMC Microbiol [Internet]. 2021;21(1):1–15. Available from: https://doi.org/10.1186/s12866-021-02403-y
Salimnia H, Fairfax MR, Lephart PR, Schreckenberger P, DesJarlais SM, Johnson JK, et al. Evaluation of the FilmArray Blood Culture Identification Panel: Results of a Multicenter Controlled Trial. J Clin Microbiol. 2016;54(3):687–98.
Schneider JG, Wood JB, Schmitt BH, Emery CL, Davis TE, Smith NW, et al. Susceptibility Provision Enhances Effective De-escalation (SPEED): Utilizing rapid phenotypic susceptibility testing in Gram-negative bloodstream infections and its potential clinical impact. J Antimicrob Chemother. 2019;74:I16–23.
Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis. 2020;7:1–12.
Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(SUPPL. 2):82–9.
Association WM. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013 Sep 22;310(20):2191–4.
Ministerio de salud. RESOLUCION NUMERO 8430 DE 1993. Minsterio de salud. 1993;1–19.
Sotgiu G, Are BM, Pesapane L, Palmieri A, Muresu N, Cossu A, et al. Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study. J Hosp Infect [Internet]. 2018;99(4):413–8. Available from: https://doi.org/10.1016/j.jhin.2018.03.033
Gupta N, Limbago BM, Patel JB, Kallen AJ, Sotgiu G, Are BM, et al. Carbapenem-resistant enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis [Internet]. 2018;53(4):413–8. Available from: https://doi.org/10.1016/j.jhin.2018.03.033
Kunz Coyne AJ, El Ghali A, Holger D, Rebold N, Rybak MJ. Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther [Internet]. 2022;11(2):661–82. Available from: https://doi.org/10.1007/s40121-022-00591-2
Esparza G. Bacterias Gram negativas resistentes a carbapenemicos en Colombia: un desafío continuo al sistema de salud. Infectio. 2020;24(2):55–6.
Marco F. Métodos moleculares para el diagnóstico de septicemia. Enferm Infecc Microbiol Clin. 2017;35(9):586–92.
Salomão MC, Guimarães T, Duailibi DF, Perondi MBM, Letaif LSH, Montal AC, et al. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate. J Hosp Infect.
Remolina S, Escobar C. DESCRIPCIÓN DE TIPOS DE CARBAPENEMASAS EXPRESADAS EN Klebsiella sp. y Pseudomonas aeruginosa EN HOSPITALES DE TERCER NIVEL DE LA CIUDAD DE BOGOTÁ, ESTUDIO DESCRIPTIVO. Univ Nac Colomb. 2018
Tamma PD, Simner PJ. Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J Clin Microbiol. 2018;56(11):1–13.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: La resistencia a carbapenémicos por bacterias gram negativas, supone una pérdida importante de medicamentos de ultima línea para su manejo. Adicionalmente, los métodos diagnósticos actuales para la identificación de estos mecanis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea8df3152cf59485d7f28424c64904be
https://repository.urosario.edu.co/handle/10336/34666
https://repository.urosario.edu.co/handle/10336/34666
